ZonMw

• dr. W. de Haan MD PhD

  ["Onderzoeksprogramma dementie"], Persoonlijke, Adaptieve, Elektrische Hersenstimulatie Thuis bij beginnende Ziekte van Alzheimer, zonmw-10510032510003-52708, 2026–2029, 1 Oct 2026

• Amsterdam UMC

  ["Onderzoeksprogramma dementie"], Persoonlijke, Adaptieve, Elektrische Hersenstimulatie Thuis bij beginnende Ziekte van Alzheimer, zonmw-10510032510003-52708, 2026–2029, 1 Oct 2026

• Amsterdam UMC Location Vrije Universiteit Amsterdam

  ["Onderzoeksprogramma dementie"], Persoonlijke, Adaptieve, Elektrische Hersenstimulatie Thuis bij beginnende Ziekte van Alzheimer, zonmw-10510032510003-52708, 2026–2029, Lead, 1 Oct 2026

• dr. RHN van der Kant

  ["Onderzoeksprogramma dementie"], Ontwikkeling van medicijnen die de bloed-hersenbarrière beschermen in ApoE4-Alzheimer., zonmw-10510032520002-52825, 2026–2027, 1 Oct 2026

• Vrije Universiteit Amsterdam

  ["Onderzoeksprogramma dementie"], Ontwikkeling van medicijnen die de bloed-hersenbarrière beschermen in ApoE4-Alzheimer., zonmw-10510032520002-52825, 2026–2027, 1 Oct 2026

• dr. M.P. Fransen

  ["Transforming Health & Care Systems"], INvolving underserved Screening Invitees in DEcision-making and Research on cancer Screening, zonmw-10750022410005-48705, 2025–2028, 1 May 2025

• dr. M.M.J. van Greevenbroek PhD

  ["EP PerMed"], EU-Calprotect: Calprotectin as a new companion biomarker and associated drug target for premature vascular aging in chronic kidney disease and type 2 diabetes, zonmw-11180102410005-48791, 2025–2028, 1 Apr 2025

• Maastricht University

  ["EP PerMed"], EU-Calprotect: Calprotectin as a new companion biomarker and associated drug target for premature vascular aging in chronic kidney disease and type 2 diabetes, zonmw-11180102410005-48791, 2025–2028, 1 Apr 2025

• dr. A.S. Meijnikman MPH PhD

  ["Veni"], Remmen van endogene ethanolproductie als nieuwe behandeling voor MASLD, zonmw-09150162310148-46789, 2024–2027, 1 Nov 2024

• Amsterdam UMC Location University of Amsterdam

  ["Veni"], Remmen van endogene ethanolproductie als nieuwe behandeling voor MASLD, zonmw-09150162310148-46789, 2024–2027, 1 Nov 2024

• Amsterdam UMC

  ["Veni"], Remmen van endogene ethanolproductie als nieuwe behandeling voor MASLD, zonmw-09150162310148-46789, 2024–2027, Lead, 1 Nov 2024

• Exalto

  ["Onderzoeksprogramma dementie"], Blood based biomarkers for early detection of Alzheimer’s Disease in NCDC, zonmw-10510042320003-44347, 2024–2029, 1 Sept 2024

• Amsterdam UMC Location Vrije Universiteit Amsterdam

  ["Onderzoeksprogramma dementie"], Blood based biomarkers for early detection of Alzheimer’s Disease in NCDC, zonmw-10510042320003-44347, 2024–2029, 1 Sept 2024

• Amsterdam UMC

  ["Onderzoeksprogramma dementie"], Blood based biomarkers for early detection of Alzheimer’s Disease in NCDC, zonmw-10510042320003-44347, 2024–2029, Lead, 1 Sept 2024

• drs. J.F. Uleman MSc

  ["Rubicon"], De cyclus doorbreken: Een systeemaanpak voor slaap, depressie en Alzheimer over de levensloop, zonmw-04520232320007-50447, 2024–2026, 1 Jun 2024

• University of Copenhagen

  ["Rubicon"], De cyclus doorbreken: Een systeemaanpak voor slaap, depressie en Alzheimer over de levensloop, zonmw-04520232320007-50447, 2024–2026, 1 Jun 2024

• prof. dr. H Holstege

  ["Joint Programming Initiative Neurodegenerative Diseases (JPND)"], Prioritization of pathways linking aging and Alzheimer’s disease to cognitive decline and dementia, zonmw-10510062320005-43238, 2024–2027, 1 Apr 2024

• Amsterdam UMC

  ["Joint Programming Initiative Neurodegenerative Diseases (JPND)"], Prioritization of pathways linking aging and Alzheimer’s disease to cognitive decline and dementia, zonmw-10510062320005-43238, 2024–2027, 1 Apr 2024

• Amsterdam UMC Location Vrije Universiteit Amsterdam

  ["Joint Programming Initiative Neurodegenerative Diseases (JPND)"], Prioritization of pathways linking aging and Alzheimer’s disease to cognitive decline and dementia, zonmw-10510062320005-43238, 2024–2027, Lead, 1 Apr 2024

• dr. L.K.M. Han PhD

  ["Veni"], Understanding biological aging: the key towards healthier and happier lives, zonmw-09150162210201-41943, 2024–2027, 14 Feb 2024

Sources: openalex.org

• Extended high frequency hearing influences cortical response amplitudes to speech

  5 Oct 2026

• Cellular senescence: six decades of discovery and reinvention

  2 Oct 2026

• Depressive symptom profiles and risk of cardiometabolic disease incidence

  10-000-1002, 2 Oct 2026

• The impact of physical activity and exercise timing on metabolic health among individuals at high risk of type 2 diabetes

  459001021, 26 Sept 2026

• Frailty of older patients is not reflected in the melanoma tumor microenvironment and treatment response to immune checkpoint blockade therapy

  09150161810003, 18 Sept 2026

• Characterization of a metabolomics signature of the brain-health-promoting MIND diet in older persons

  11 Sept 2026

• Self-Feeding Living Materials Enabled by Cell Responsive Glycogen Nanoparticles as Metabolic Batteries

  1 Sept 2026

• Lipoprotein(a) distributions and trial eligibility thresholds for Lp(a)-lowering therapies in the general population: The Rotterdam Study

  31 Aug 2026

• A Comprehensive Assessment of the Shared Genetic Architecture between Myopia and Open-Angle Glaucoma

  22 Jul 2026

Sources: api.crossref.org, pubmed.ncbi.nlm.nih.gov

• A Harmonized Visual Reading Framework for Tau PET Staging in Alzheimer Disease

  Grants or research support, 21 Sept 2026

• Cortical thickness changes precede high levels of amyloid by at least 7 years

  Grants or research support, 19 Aug 2026

Sources: pubmed.ncbi.nlm.nih.gov

• The plasma proteins GSN, F2, CRTAC1, and HP reflect multigenerational health, longevity, and resilience

  medRxiv, 9 Feb 2026